Press Releases

Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments. "C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a

AccessDx Laboratory, a nationwide provider of precision medicine and diagnostics solutions, today announced its expanded integration with PointClickCare, a leading healthcare technology platform enabling meaningful care collaboration and real-time patient insights. This integration allows for the seamless delivery of pharmacogenomic (PGx) risk assessments, advanced diagnostic test results, and ongoing PGx monitoring, empowering them to deliver better and more personalized resident care, allow

Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has been granted a patent in India covering a prolonged-release pharmaceutical formulation, utilizing liposomes to encapsulate cannabinoids. This granted patent protects Innocan's synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of Synthetic CBD into the bloodstream. LPT-CBD received positive

dsm-firmenich, a leading innovator in health, nutrition, and beauty, today reveals new clinical data confirming that the bioavailability of cannabidiol (CBD)-based therapies can be enhanced in oral solid dosage forms. The clinical trial results demonstrated that dsm-firmenich’s CBD drug product intermediate, CBtru®, is absorbed into the bloodstream at a similar level compared to Epidiolex®, the first (and to this date only) commercially approved CBD drug product on the market, w

Alume Biosciences, a late-clinical stage biotechnology company developing nerve illuminating technology to potentially make surgery safer, today announced the appointment of Kaveri Parker, Ph.D. as Chief Business Officer. Dr. Parker is a forward-thinking biopharma leader and joins Alume Biosciences with deep experience in strategy and operations leadership roles. "We are pleased to welcome Kaveri to our growing team and are confident her vision will help us advance the field of

Silo Pharma, Inc. a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University. The provisional patent cov

Septerna, Inc. a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two unanticipated severe (Grade 3) even

Clinigen, the global speciality pharmaceutical services group, and Essential Pharma, an international specialty pharmaceutical group, today announced an expansion of their JAPAC collaboration, aimed at driving continued patient access to four therapies in Japan and Korea, and strengthening their combined market presence in the region. This expanded collaboration encompasses several new market authorisation transfer and exclusive distribution agreements. Building on their 2024 agreem

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that XPOVIO® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM) who have received at least two prior therapies, has been approved for reimbursement in Taiwa

Navega Therapeutics, a leading epigenetic gene therapy company, is pleased to announce the addition of four senior advisors.  The addition of these experienced entrepreneurs and scientific experts will support the team on technical and business topics as the company continues to grow. The new advisors will contribute their talents in gene therapy product development, AAV manufacturing, and business strategy with more than 125 years of combined experience in this field.  &n